Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer Castration-resistant Prostate Cancer
- Breast Cancer
- Colo-rectal Cancer
- Lung Cancer (Non-Small Cell)
- Pancreas Cancer, Duct Cell Adenocarcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- MBrace Therapeutics
- Last updated on ClinicalTrials.gov
- February 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, CA
Michigan · 1
- START, Midwest · Grand Rapids, MI
New Jersey · 1
- START, Astera · East Brunswick, NJ
Texas · 2
- NEXT, Dallas · Irving, TX
- START San Antonio · San Antonio, TX
Utah · 1
- START, Mountain Region · West Valley City, UT
Virginia · 1
- NEXT, Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.